Fosfocreatine
As of the edition of 20 October 2026, Fosfocreatine is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Neoton
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- Alfasigma; 3 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Mental health; Heart and blood vessels; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 2 |